141 related articles for article (PubMed ID: 17637563)
21. The cytotoxic ribonuclease onconase targets RNA interference (siRNA).
Zhao H; Ardelt B; Ardelt W; Shogen K; Darzynkiewicz Z
Cell Cycle; 2008 Oct; 7(20):3258-61. PubMed ID: 18927512
[TBL] [Abstract][Full Text] [Related]
22. Linker length affects expression and bioactivity of the onconase fusion protein in Pichia pastoris.
Yang GG; Xu XY; Ding Y; Cui QQ; Wang Z; Zhang QY; Shi SH; Lv ZY; Wang XY; Zhang JH; Zhang RG; Xu CS
Genet Mol Res; 2015 Dec; 14(4):19360-70. PubMed ID: 26782589
[TBL] [Abstract][Full Text] [Related]
23. Role of the N terminus in RNase A homologues: differences in catalytic activity, ribonuclease inhibitor interaction and cytotoxicity.
Boix E; Wu Y; Vasandani VM; Saxena SK; Ardelt W; Ladner J; Youle RJ
J Mol Biol; 1996 Apr; 257(5):992-1007. PubMed ID: 8632481
[TBL] [Abstract][Full Text] [Related]
24. Synergism between a novel amphibian oocyte ribonuclease and lovastatin in inducing cytostatic and cytotoxic effects in human lung and pancreatic carcinoma cell lines.
Mikulski SM; Viera A; Darzynkiewicz Z; Shogen K
Br J Cancer; 1992 Aug; 66(2):304-10. PubMed ID: 1503903
[TBL] [Abstract][Full Text] [Related]
25. A cytotoxic ribonuclease. Study of the mechanism of onconase cytotoxicity.
Wu Y; Mikulski SM; Ardelt W; Rybak SM; Youle RJ
J Biol Chem; 1993 May; 268(14):10686-93. PubMed ID: 8486718
[TBL] [Abstract][Full Text] [Related]
26. Enhancement of vincristine cytotoxicity in drug-resistant cells by simultaneous treatment with onconase, an antitumor ribonuclease.
Rybak SM; Pearson JW; Fogler WE; Volker K; Spence SE; Newton DL; Mikulski SM; Ardelt W; Riggs CW; Kung HF; Longo DL
J Natl Cancer Inst; 1996 Jun; 88(11):747-53. PubMed ID: 8637029
[TBL] [Abstract][Full Text] [Related]
27. Ribonucleases as potential modalities in anticancer therapy.
Ardelt W; Ardelt B; Darzynkiewicz Z
Eur J Pharmacol; 2009 Dec; 625(1-3):181-9. PubMed ID: 19825371
[TBL] [Abstract][Full Text] [Related]
28. Interaction of onconase with the human ribonuclease inhibitor protein.
Turcotte RF; Raines RT
Biochem Biophys Res Commun; 2008 Dec; 377(2):512-514. PubMed ID: 18930025
[TBL] [Abstract][Full Text] [Related]
29. Arginine residues are more effective than lysine residues in eliciting the cellular uptake of onconase.
Sundlass NK; Raines RT
Biochemistry; 2011 Nov; 50(47):10293-9. PubMed ID: 21980976
[TBL] [Abstract][Full Text] [Related]
30. Quantitative analysis, using MALDI-TOF mass spectrometry, of the N-terminal hydrolysis and cyclization reactions of the activation process of onconase.
Ribó M; Bosch M; Torrent G; Benito A; Beaumelle B; Vilanova M
Eur J Biochem; 2004 Mar; 271(6):1163-71. PubMed ID: 15009195
[TBL] [Abstract][Full Text] [Related]
31. Onconase: an unusually stable protein.
Notomista E; Catanzano F; Graziano G; Dal Piaz F; Barone G; D'Alessio G; Di Donato A
Biochemistry; 2000 Aug; 39(30):8711-8. PubMed ID: 10913282
[TBL] [Abstract][Full Text] [Related]
32. Induction of differentiation of leukaemic (HL-60) or prostate cancer (LNCaP, JCA-1) cells potentiates apoptosis triggered by onconase.
Halicka HD; Murakami T; Papageorgio CN; Mittelman A; Mikulski SM; Shogen K; Darzynkiewicz Z
Cell Prolif; 2000 Dec; 33(6):407-17. PubMed ID: 11101012
[TBL] [Abstract][Full Text] [Related]
33. Structural basis for catalysis by onconase.
Lee JE; Bae E; Bingman CA; Phillips GN; Raines RT
J Mol Biol; 2008 Jan; 375(1):165-77. PubMed ID: 18001769
[TBL] [Abstract][Full Text] [Related]
34. Disruption of shape-complementarity markers to create cytotoxic variants of ribonuclease A.
Rutkoski TJ; Kurten EL; Mitchell JC; Raines RT
J Mol Biol; 2005 Nov; 354(1):41-54. PubMed ID: 16188273
[TBL] [Abstract][Full Text] [Related]
35. Ranpirnase as a potential antitumor ribonuclease treatment for mesothelioma and other malignancies.
Beck AK; Pass HI; Carbone M; Yang H
Future Oncol; 2008 Jun; 4(3):341-9. PubMed ID: 18518759
[TBL] [Abstract][Full Text] [Related]
36. Ribonucleases as novel chemotherapeutics : the ranpirnase example.
Lee JE; Raines RT
BioDrugs; 2008; 22(1):53-8. PubMed ID: 18215091
[TBL] [Abstract][Full Text] [Related]
37. [Effective expression of ribonuclease-onconase in Escherichia coli and assaying its cytotoxic potential].
Xu GF; Wang QC; Gong XG; Fei J
Shi Yan Sheng Wu Xue Bao; 2004 Jun; 37(3):227-31. PubMed ID: 15323425
[TBL] [Abstract][Full Text] [Related]
38. Influence of onconase in the therapeutic potential of PARP inhibitors in A375 malignant melanoma cells.
Raineri A; Prodomini S; Fasoli S; Gotte G; Menegazzi M
Biochem Pharmacol; 2019 Sep; 167():173-181. PubMed ID: 31185226
[TBL] [Abstract][Full Text] [Related]
39. Endowing human pancreatic ribonuclease with toxicity for cancer cells.
Leland PA; Staniszewski KE; Kim BM; Raines RT
J Biol Chem; 2001 Nov; 276(46):43095-102. PubMed ID: 11555655
[TBL] [Abstract][Full Text] [Related]
40. Contribution of structural peculiarities of onconase to its high stability and folding kinetics.
Arnold U; Schulenburg C; Schmidt D; Ulbrich-Hofmann R
Biochemistry; 2006 Mar; 45(11):3580-7. PubMed ID: 16533040
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
